Skip to main content

Advertisement

SpringerLink
Log in

Prophylactic Magnesium Sulfate for Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-analysis

  • Review Article
  • Published:
Neurocritical Care Aims and scope Submit manuscript

Abstract

Delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage is a cause of considerable morbidity and mortality. Magnesium sulfate has been proposed as a prophylactic intervention for angiographic vasospasm and to improve clinical outcomes. A systematic review was conducted to determine the evidence for the prophylactic use of magnesium sulfate in aneurysmal subarachnoid hemorrhage. Medline, Embase, Cochrane library, clinicaltrials.gov, and controlled-trials.com were searched with a comprehensive search strategy. 2,035 records were identified in the initial search and 1,574 remained after removal of duplicates. Randomized, parallel group, controlled trials of magnesium sulfate in patients with aneurysmal subarachnoid hemorrhage were included. A total of ten studies were included. Review Manager and GRADE software were used to synthesize the results. The summary effect for Glasgow outcome scale and the modified Rankin scale is a risk ratio (RR) of 0.93 [95 % confidence interval (CI) 0.82–1.06]. The RR for mortality is 0.95 [95 % CI 0.76–1.17]. Delayed cerebral ischemia has a RR of 0.54 [95 % CI 0.38–0.75], which is the only outcome with a statistically significant summary effect measure favoring magnesium treatment. Delayed ischemic neurological deficit has a RR of 0.93 [95 % CI 0.62–1.39]. Transcranial doppler vasospasm has a RR of 0.72 [95 % CI 0.51–1.03]. Current evidence does not support the prophylactic use of magnesium sulfate in aneurysmal subarachnoid hemorrhage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Vergouwen MDI, Vermeulen M, van Gijn J, Rinkel GJE, Wijdicks EF, Muizelaar JP, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a Multidisciplinary Research Group. Stroke. 2010;41:2391–5.

    Article  PubMed  Google Scholar 

  2. GRADEpro. [Computer program]. Version 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008.

  3. Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.

  4. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:1711–37.

    Article  PubMed  Google Scholar 

  5. Chen T, Carter BS. Role of magnesium sulfate in aneurysmal subarachnoid hemorrhage management: a meta-analysis of controlled clinical trials. Asian J Neurosurg. 2011;6(1):26–31.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ma L, Liu W, Zhang J, Chen G, Fan J, Sheng H. Magnesium sulphate in the management of patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of prospective controlled trials. Brain Inj. 2010;24(5):730–5.

    Article  PubMed  Google Scholar 

  7. Wong GK, Chan MT, Gin T, Poon WS. Intravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: current status. Acta Neurochir Suppl. 2011;110(Pt 2):169–73.

    PubMed  Google Scholar 

  8. Aidaros M, Goda T, El-Sharkawy KAM. The role of magnesium sulphate in treatment of subarachnoid hemorrhage and its effect on outcome. Egypt J Neurol Psychiatry Neurosurg. 2011;48(1):79–83.

    Google Scholar 

  9. Akdemir H, Kulakszoglu EO, Tucer B, Menku A, Postalc L, Gunald O. Magnesium sulfate therapy for cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurg Q. 2009;19(1):35–9.

    Article  Google Scholar 

  10. Baiocchi M, Grassetto A, Ori C. Potential role of continuous magnesium infusion to prevent vasospasm and consequent ischaemic deficit correlated to subarachnoid haemorrhage. Acta Anaesthesiol Italica. 2006;57(2–3):131–45.

    Google Scholar 

  11. Dorhout Mees SM, Algra A, Vandertop WP, van Kooten F, Kuijsten HAJM, Boiten J et al. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet. 2012;6736(12)60724–60727. doi:10.1016/S0140-.

  12. Muroi C, Terzic A, Fortunati M, Yonekawa Y, Keller E. Magnesium sulfate in the management of patients with aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, dose-adapted trial. Surg Neurol. 2008;69(1):33–9 (discussion 39).

    Article  PubMed  Google Scholar 

  13. van den Bergh WM, Algra A, van Kooten F, Dirven CM, van Gijn J, Vermeulen M, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2005;36(5):1011–5.

    Article  PubMed  Google Scholar 

  14. Veyna RS, Seyfried D, Burke DG, Zimmerman C, Mlynarek M, Nichols V, et al. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2002;96(3):510–4.

    Article  PubMed  CAS  Google Scholar 

  15. Westermaier T, Stetter C, Vince GH, Pham M, Tejon JP, Eriskat J, et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study. Crit Care Med. 2010;38(5):1284–90.

    PubMed  CAS  Google Scholar 

  16. Wong GK, Chan MT, Boet R, Poon WS, Gin T. Intravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: a prospective randomized pilot study. J Neurosurg Anesthesiol. 2006;18(2):142–8.

    Article  PubMed  Google Scholar 

  17. Wong GK, Poon WS, Chan MT, Boet R, Gin T, Ng SC, Zee BC. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled. Multicenter Phase III trial. Stroke. 2010;41:921–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

Deven Reddy, Aria Fallah, Jo-Anne Petropoulos, Forough Farrokhyar, and Draga Jichici declare that they have no conflict of interest. R.L. Macdonald receives grant support from the Physicians Services Incorporated Foundation, Brain Aneurysm Foundation, Canadian Stroke Network, and the Heart and Stroke Foundation of Ontario. R.L. Macdonald is a consultant for Actelion Pharmaceuticals and Chief Scientific Officer of Edge Therapeutics, Inc.

Author information

Authors and Affiliations

  1. Division of Neurosurgery, McMaster University, Hamilton General Hospital, Rm. 8 North 8N-01, 237 Barton Street East, Hamilton, ON, L8L 2X2, Canada

    Deven Reddy

  2. Division of Neurosurgery, University of Toronto, Toronto, ON, Canada

    Aria Fallah & R. Loch Macdonald

  3. Health Sciences Library, McMaster University, Hamilton, ON, Canada

    Jo-Anne Petropoulos

  4. Department of Surgery, McMaster University, Hamilton, ON, Canada

    Forough Farrokhyar

  5. Division of Critical Care, McMaster University, Hamilton, ON, Canada

    Draga Jichici

Authors
  1. Deven Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aria Fallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jo-Anne Petropoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Forough Farrokhyar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Loch Macdonald
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Draga Jichici
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deven Reddy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reddy, D., Fallah, A., Petropoulos, JA. et al. Prophylactic Magnesium Sulfate for Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-analysis. Neurocrit Care 21, 356–364 (2014). https://doi.org/10.1007/s12028-014-9964-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-014-9964-0

Keywords

Search

Navigation